{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"New Data Emphasize the Therapeutic Value of Biologics in Control of Severe Eosinophilic Asthma - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"ouRijOEyBM\"><a href=\"https:\/\/themedicalxchange.com\/en\/2016\/10\/19\/european-respiratory-society-ers-international-c-3\/\">New Data Emphasize the Therapeutic Value of Biologics in Control of Severe Eosinophilic Asthma<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2016\/10\/19\/european-respiratory-society-ers-international-c-3\/embed\/#?secret=ouRijOEyBM\" width=\"600\" height=\"338\" title=\"&#8220;New Data Emphasize the Therapeutic Value of Biologics in Control of Severe Eosinophilic Asthma&#8221; &#8212; The Medical Xchange\" data-secret=\"ouRijOEyBM\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2016\/10\/2360_ERS_2016_EN_Fig_1.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"London \u2013 Data presented at the 2016 ERS Congress reinforce the premise that biologics have a central role in the control of the severe eosinophilic asthma phenotype. These studies include phase 3 data with a new monoclonal antibody (MAb) targeting the interleukin-5 (IL-5) receptor, new analyses of an already approved IL-5 inhibitor in a refractory population, and a paediatric study of the first approved biologic for asthma, which is targeted at immunoglobulin E (IgE). All of these agents have been associated with significant reductions in rate of exacerbations relative to placebo. Biologics targeting other mediators and pathways of eosinophil activation are expected, although a newly completed phase 3 study with a MAb targeting interleukin-13 (IL-13) was negative."}